Mangalam Drugs & Organics Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 970.46 million. Revenue was INR 973.36 million. Net income was INR 4.98 million. Basic earnings per share from continuing operations was INR 0.31. Diluted earnings per share from continuing operations was INR 0.31.
For the nine months, sales was INR 2,654.16 million. Revenue was INR 2,663.6 million. Net loss was INR 126.02 million. Basic loss per share from continuing operations was INR 7.96. Diluted loss per share from continuing operations was INR 7.96.